Orion Corporation

Orion-yhtyma Oy

Orion Corporation/orion Pharmaceutica

Heimo O Haikala

Pentti T Nore

Erkki J Honkanen

Jarmo J Pystynen

Jouko Levijoki

Aino K Pippuri

Reijo J Backstrom

Anne M Luiro

Piero Pollesello

Juha Kaivola

Carola Tilgmann

Jorma V Haarala

Kari K Lonnberg

Tom Wikberg

Petri Kaheinen

Kari L&ouml;nnberg

Arto J Karjalainen

Erkki A Nissinen

Eija Tiainen

Kalevi E Heinola

Martti Ovaska

Seppo Parhi

Jukka Tenhunen

Reijo B&auml;ckstr&ouml;m

Reijo B Ackstr Om

Pentti Pöder

Minja Hyttilä-Hopponen

Minna Ruotsalainen

Kari Lönnberg

Ismo Ulmanen

Juoko M Levijoki

A method for the prevention of thrombotic, embolic and/or hemorrhagic disorders, such as cerebral infarction (stroke) or myocardial infarction, by administering levosimendan or its metabolite (II) or any of their pharmaceutically acceptable salts to a mammal in need of such prevention.

Method for the prevention of thromboembolic disorders

A combination therapy for the treatment of heart failure comprises administering a combination of levosimendan or a pharmaceutically acceptable salt thereof and a beta-adrenergic receptor antagonist to a patient. The combination synergistically reduces mortality in heart failure patients.

Combination therapy for the treatment of heart failure

The use of mitochondrial Kchannel openers, particularly compounds of general formula (I), for the treatment or prevention of inflammation by inducing apoptosis of inflammatory cells.

Anti-inflammatory agents

Pyridazinyl phenyl hydrazones useful against congestive heart failure

A method for obtaining direct dilatation of the coronary arteries by administering a therapeutically effective amount of a phospholamban inhibitor is described. Compounds which are effective in relieving the inhibitory effects of phospholamban on cardiac sarcoplasmic reticulum Ca,-ATPase are also described.

Phospholamban inhibitors and a method for increasing coronary flow

A method for the prevention and treatment of stunning of the heart subsequent to ischemia-reperfusion is described. The method comprises administering a therapeutically effective amount of a phospholamban inhibitor to a patient. Phospholamban inhibitors relieve the inhibitory effect of phospholamban on cardiac sarcoplasmic reticulum Ca.sup.2+ -ATPase.

Method for the prevention and treatment of stunned myocardium

A method for the treatment of neurohumoral imbalance caused by alterations of cardiac function to prevent the development of heart failure comprises administering an effective amount of (R)-�4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl!acetamide to a mammal in need of such treatment.

Use of a pyridazinone derivative

The compound (-)-[[4-(1,4,5,6 tetrahydro-4-methyl-6-oxo-3 pyridazinyl) phenyl]-hydrazono] propane dinitrile and its salts are prepared and used for treating congestive heart failure.

(-)-[[4-(1,4,5,6-tetrahydro-4-m

Diastereomeric intermediate salts of formulae (IIIa) or (IIIb) ##STR1## are prepared.

Anti-ischemic medicament

New heterocyclic compounds of formula I ##STR1## In which Het means one of following groups; ##STR2## wherein R.sub.11, R.sub.13 and R.sub.14 mean independently hydrogen, hydroxymethyl or lower alkyl group, Z means S, O or NH; A means valency bond, --CH.dbd.CH--, or --CH.sub.2 --CH.sub.2 --group; R.sub.1 and R.sub.2 independently mean nitro, cyano, halogen, amino, carboxamido, aryl, aroyl, pyridyl, alkoxycarbonyl, acyl or one of following groups; ##STR3## wherein R.sub.6 means hydrogen or lower alkyl group, R.sub.8 means lower alkyl, R.sub.7 means cyano or COOR.sub.10, wherein R.sub.10 means hydrgen or lower alkyl or R.sub.1 and R.sub.2 together form a susbtituted or unsubstituted 5 or 6 membered ring which may contain 1 to 2 heteroatom N; R.sub.3, R.sub.4, and R.sub.5 means independently hydrogen, hydroxy or lower alkyl group; Y means N or CH. The compounds may be used in the treatment of congestive heart failure.

Thiadiazines and pharmaceutical compositions thereof as well as method

Substituted benzylideneiminophyenylpyridazinones or dihydropyridazinones of formula I ##STR1## in which R.sub.1 and R.sub.8 independently mean hydrogen or lower alkyl, R2 is hydrogen, lower alkyl, trifluoromethyl, hydroxy alkyl, halogen alkyl, alkoxy alkyl, pyridyl, furyl, thienyl or cycloalkyl or one of optionally substituted groups; aryl, aralkyl, aralkenyl or nitrogen containing heterocyclic ring joining through an alkyl or alkenyl group and R.sub.3, R.sub.4 and R.sub.5 independently mean hydrogen, lower alkyl, hydroxy alkyl, halogen, hydroxy, alkoxy, acyloxy, aroyloxy, formyl, acyl, cyano, amino, carboxy or trifluoromethyl, R.sub.6 and R.sub.7 independently mean hydrogen, amino, lower alkyl, hydroxy, nitro or cyano or R.sub.2 and R.sub.7 together form a --CH.sub.2 --NH-- or --CH.dbd.N-- group and A means phenyl, naphtyl or a nitrogen containing heterocyclic ring. The compounds may be used in the treatment of congestive heart failure.

Substituted pyridazinones

New heterocyclic compounds of formula I ##STR1## in which Het means one of following groups; ##STR2## wherein R.sub.11, R.sub.13 and R.sub.14 mean independently hydrogen, hydroxymethyl or lower alkyl group, Z means S, O or NH; A means valency bond, --CH.dbd.CH--, or --CH.sub.2 --CH.sub.2 -- group; R.sub.1 and R.sub.2 independently mean nitro, cyano, halogen, amino, carboxamido, aryl, aroyl, pyridyl, alkoxycarbonyl, acyl or one of following groups; ##STR3## wherein R.sub.6 means hydrogen or lower alkyl group, R.sub.8 means lower alkyl, R.sub.7 means cyano or COOR.sub.10, wherein R.sub.10 means hydrogen or lower alkyl or R.sub.1 and R.sub.2 together form a substituted or unsubstituted 5 or 6 membered ring which may contain 1 or 2 heteroatom N; R.sub.3, R.sub.4, and R.sub.5 mean independently hydrogen, hydroxy or lower alkyl group; Y means N or CH. The compounds may be used in the treatment of congestive heart failure.

Triazinone compounds compositions thereof and metal of use

Growing community of inventors

Espoo, Finland

Heimo O Haikala